Q32 Bio (FRA:DB0) Total Liabilities: €15.02 Mil (As of Mar. 2026)


FRA:DB0 Q32 Bio Inc FRA:DB0
17 GF Score
Price €11.33
! 6 Warning Signs
View Full Analysis

What is Q32 Bio Total Liabilities?

Q32 Bio FRA:DB0 -0.18% 17 Total Liabilities is €15.02 Mil as of Mar. 2026. GuruFocus rates FRA:DB0 with a GF Score™ of 17/100. The stock has 6 warning signs investors should review.

Q32 Bio's Total Liabilities for the quarter that ended in Mar. 2026 was €15.02 Mil.

Q32 Bio's quarterly Total Liabilities declined from Sep. 2025 (€64.95 Mil) to Dec. 2025 (€16.88 Mil) and declined from Dec. 2025 (€16.88 Mil) to Mar. 2026 (€15.02 Mil).

Q32 Bio's annual Total Liabilities declined from Dec. 2023 (€210.89 Mil) to Dec. 2024 (€82.76 Mil) and declined from Dec. 2024 (€82.76 Mil) to Dec. 2025 (€16.88 Mil).

Q32 Bio Total Liabilities Historical Data

* Premium members only.

The historical data trend for Q32 Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio Total Liabilities Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
110.06 181.71 210.89 82.76 16.88

Q32 Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.85 67.93 64.95 16.88 15.02
FRA:DB0
17GF Score
Q32 Bio Inc FRA:DB0
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q32 Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Q32 Bio's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.689+(7.187+0.00099999999999856
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=16.88

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=52.757-35.88
=16.88

Q32 Bio's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.229+(5.789+1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=15.02

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=55.079-40.061
=15.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €15.02 Mil mean?
Q32 Bio (FRA:DB0) has a Total Liabilities of €15.02 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Q32 Bio and its competitors.
Is Q32 Bio's Total Liabilities too high?
Q32 Bio's current Total Liabilities is €15.02 Mil. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's Total Liabilities compare to CAMP and CDXS?
Q32 Bio's Total Liabilities of €15.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Q32 Bio and its competitors. Q32 Bio's current Total Liabilities is €15.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (FRA:DB0) has a current Total Liabilities of €15.02 Mil. The current Total Liabilities is €15.02 Mil. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Q32 Bio (FRA:DB0), the current Total Liabilities is €15.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q32 Bio Business Description

Other Exchanges QTTB:USA
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for FRA:DB0

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.33
Price